Hydroxysafflor yellow A protects against chronic carbon tetrachloride-induced liver fibrosis

European Journal of Pharmacology

Volumn 660, Issue 2-3, 2011, Pages 438-444

  Zhang, Yingbo ^a   Guo, Jia ^a   Dong, Hanying ^a   Zhao, Xuemei ^a   Zhou, Li ^a   Li, Xueyan ^a   Liu, Jicheng ^a   Niu, Yingcai ^a  

^a QIQIHAR MEDICAL UNIVERSITY   (China)

Author keywords

Collagenase activity; Hydroxysafflor yellow A; Liver fibrosis; Transforming growth factor 1

Indexed keywords

COLLAGEN FIBER; HYDROXYPROLINE; HYDROXYSAFFLOW YELLOW A; LIVER PROTECTIVE AGENT; MESSENGER RNA; OLIVE OIL; PLANT MEDICINAL PRODUCT; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ALPHA SMOOTH MUSCLE ACTIN GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLAGEN ALPHA TYPE 1 GENE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; GENE; GENE EXPRESSION REGULATION; LIVER FIBROSIS; LIVER PROTECTION; MALE; MATRIX METALLOPROTEINASE 9 GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; TISSUE INHIBITOR OF METALLOPROTEINASE 1 GENE;

ANIMALS; CARBON TETRACHLORIDE; CHALCONE; CHRONIC DISEASE; COLLAGEN TYPE I; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEPATIC STELLATE CELLS; LIVER CIRRHOSIS; MALE; MATRIX METALLOPROTEINASE 9; PHOSPHORYLATION; QUINONES; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SMAD4 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79956075733     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.04.015     Document Type: Article

References (46)

1. Antony, M.L., Nair, R., Sebastian, P., Karunagaran, D., 2010. Changes in expression, and/or mutations in TGF-beta receptors (TGF-beta RI and TGF-beta RII) and Smad 4 in human ovarian tumors. J. Cancer Res. Clin. Oncol. 36, 351-361.
2. Arocho, A., Chen, B., Ladanyi, M., Pan, Q., 2006. Validation of the 2-deltadeltaCt calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts. Diagn. Mol. Pathol. 15, 56-61.
3. Bares, J.M., Berger, J., Nelson, J.E., Messner, D.J., Schildt, S., Standish, L.J., Kowdley, K.V., 2008. Silybin treatment is associated with reduction in serum ferritin in patients with chronic hepatitis C. J. Clin. Gastroenterol. 42, 937-944.
4. Borkham-Kamphorst, E., Herrmann, J., Stoll, D., Treptau, J., Gressner, A.M., Weiskirchen, R., 2004. Dominant-negative soluble PDGF-beta receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis. Lab. Invest. 84, 766-777.
5. Chan, T.M., Wu, P.C., Li, F.K., Lai, C.L., Cheng, I.K., Lai, K.N., 1998. Treatment of fibrosing cholestatic hepatitis with lamivudine. Gastroenterology 115, 177-181. (Pubitemid 28307303)
6. Chiao, P.J., Hunt, K.K., Grau, A.M., Abramian, A., Fleming, J., Zhang, W., Breslin, T., Abbruzzese, J.L., Evans, D.B., 1999. Tumor suppressor gene Smad4/DPC4, its downstream target genes, and regulation of cell cycle. Ann. N. Y. Acad. Sci. 30 (880), 31-37.
7. Díaz-Gil, J.J., García-Monzón, C., Rúa, C., Martín-Sanz, P., Cereceda, R.M., Miquilena-Colina, M.E., Machín, C., Fernández-Martínez, A., García-Cañero, R., 2008. The anti-fibrotic effect of liver growth factor is associated with decreased intrahepatic levels of matrix metalloproteinases 2 and 9 and transforming growth factor beta 1 in bile duct-ligated rats. Histol. Histopathol. 23, 583-591.
8. Fibbi, G., Pucci, M., D'Alessio, S., Grappone, C., Pellegrini, G., Salzano, R., Casini, A., Milani, S., Del Rosso, M., 2001. Transforming growth factor beta-1 stimulates invasivity of hepatic stellate cells by engagement of the cell-associated fibrinolytic system. Growth Factors 19, 87-100. (Pubitemid 33133367)
9. Freedman, N.D., Curto, T.M., Morishima, C., Seeff, L.B., Goodman, Z.D., Wright, E.C., Sinha, R., Everhart, J.E., HALT-C Trial Group, 2011. Silymarin use and liver disease progression in the hepatitis c antiviral long-term treatment against cirrhosis trial. Aliment Pharmacol Ther. 33, 127-137.
10. Fritz, E., Hammer, J., 2009. Gastrointestinal symptoms in patients with liver cirrhosis are linked to impaired quality of life and psychological distress. Eur. J. Gastroenterol. Hepatol. 21, 370-375.
11. Fu, Y., Zheng, S., Lin, J., Ryerse, J., Chen, A., 2008. Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol. Pharmacol. 73, 399-409.
12. Gailhouste, L., Le Grand, Y., Odin, C., Guyader, D., Turlin, B., Ezan, F., Désille, Y., Guilbert, T., Bessard, A., Frémin, C., Theret, N., Baffet, G., 2010. Fibrillar collagen scoring by second harmonic microscopy: a new tool in the assessment of liver fibrosis. J. Hepatol. 52, 398-406.
13. Gassmann, P., Spieker, T., Haier, J., Schmidt, F., Mardin, W.A., Senninger, N., 2010. Prognostic impact of underlying liver fibrosis and cirrhosis after curative resection of hepatocellular carcinoma. World J. Surg. 34, 2442-2451.
14. Gebhardt, R., 2002. Oxidative stress, plant-derived antioxidants and liver fibrosis. Planta. Med. 68, 289-296.
15. George, J., Roulot, D., Koteliansky, V.E., Bissell, D.M., 1999. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc. Natl. Acad. Sci. U. S. A. 96, 12719-12724.
16. Grizzi, F., Franceschini, B., Gagliano, N., Moscheni, C., Annoni, G., Vergani, C., Hermonat, P.L., Chiriva-Internati, M., Dioguardi, N., 2003. Mast cell density, hepatic stellate cell activation and TGF-beta1 transcripts in the aging Sprague-Dawley rat during early acute liver injury. Toxicol. Pathol. 31, 173-178.
17. Hsu, Y.C., Chiu, Y.T., Cheng, C.C., Wu, C.F., Lin, Y.L., Huang, Y.T., 2007. Antifibrotic effects of tetrandrine on hepatic stellate cells and rats with liver fibrosis. J. Gastroenterol. Hepatol. 22, 99-111.
18. Iredale, J., 2008. Defining therapeutic targets for liver fibrosis: exploiting the biology of inflammation and repair. Pharmacol. Res. 58, 129-136.
19. Jackson, P.L., Xu, X., Wilson, L., Weathington, N.M., Clancy, J.P., Blalock, J.E., Gaggar, A., Kaimori, A., Potter, J., Kaimori, J.Y., Wang, C., Mezey, E., Koteish, A., 2007. Transforming growth factor-beta1 induces an epithelial-to-mesenchymal transition state inmouse hepatocytes in vitro. J. Biol. Chem. 282, 22089-22101.
20. Jackson, P.L., Xu, X., Wilson, L., Weathington, N.M., Clancy, J.P., Blalock, J.E., Gaggar, A., 2010a. Human neutrophil elastase-mediated cleavage sites of MMP-9 and TIMP-1: implications to cystic fibrosis proteolytic dysfunction. Mol. Med. 16, 159-166.
21. Jackson, B.C., Nebert, D.W., Vasiliou, V., 2010b. Update of human and mouse matrix metalloproteinase families. Hum. Genomics 4, 194-201.
22. Kato, J., Ido, A., Hasuike, S., Uto, H., Hori, T., Hayashi, K., Murakami, S., Terano, A., Tsubouchi, H., 2004. Transforming growth factor-beta-induced stimulation of formation of collagen fiber network and anti-fibrotic effect of taurine in an in vitro model of hepatic fibrosis. Hepatol. Res. 30, 34-41.
23. Le Bail, B., Faouzi, S., Boussarie, L., Balabaud, C., Bioulac-Sage, P., Rosenbaum, J., 1997. Extracellular matrix composition and integrin expression in early hepatocarcinogenesis in human cirrhotic liver. J. Pathol. 181, 330-337. (Pubitemid 27156848)
24. Lee, S.H., Chae, K.S., Sohn, D.H., 2004. Identification of expressed sequence tags of genes expressed highly in the activated hepatic stellate cell. Arch. Pharm. Res. 27, 422-428.
25. Li, J.T., Liao, Z.X., Ping, J., Xu, D., Wang, H., 2008. Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies. J. Gastroenterol. 43, 419-428. (Pubitemid 351997878)
26. Li, F., Zeng, B., Chai, Y., Cai, P., Fan, C., Cheng, T., 2009. The linker region of Smad2 mediates TGF-beta-dependent ERK2-induced collagen synthesis. Biochem. Biophys. Res. Commun. 386, 289-293.
27. Liu, X., Hu, H., Yin, J.Q., 2006. Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver Int. 26, 8-22.
28. Lou, J.L., Jiang, M.N., Li, C., Zhou, Q., He, X., Lei, H.Y., Li, J., Jia, Y.J., 2010. Herb medicine Gan-fu-kang attenuates liver injury in a rat fibrotic model. J. Ethnopharmacol. 128, 131-138.
29. Mata-Santos, H.A., Lino, F.G., Rocha, C.C., Paiva, C.N., Castelo Branco, M.T., Pyrrho, Ados S., 2010. Silymarin treatment reduces granuloma and hepatic fibrosis in experimental schistosomiasis. Parasitol. Res. 107, 1429-1434.
30. Moreno, M., Chaves, J.F., Sancho-Bru, P., Ramalho, F., Ramalho, L.N., Mansego, M.L., Ivorra, C., Dominguez, M., Conde, L., Millán, C., Marí, M., Colmenero, J., Lozano, J.J., Jares, P., Vidal, J., Forns, X., Arroyo, V., Caballería, J., Ginès, P., Bataller, R., 2010. Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans. Hepatology 51, 974-985.
31. Nakamuta, M., Kohjima, M., Fukushima, M., Morizono, S., Kotoh, K., Kobayashi, N., Enjoji, M., 2005. Cyclosporine suppresses cell growth and collagen production in hepatic stellate cells. Transplant Proc. 37, 4598-4602. (Pubitemid 43016090)
32. Passino, M.A., Adams, R.A., Sikorski, S.L., Akassoglou, K., 2007. Regulation of hepatic stellate cell differentiation by the neurotrophin receptor p75NTR. Science 315, 1853-1856. (Pubitemid 46580146)
33. Purohit, V., Russo, D., Coates, P.M., 2004. Role of fatty liver, dietary fatty acid supplements, and obesity in the progression of alcoholic liver disease: introduction and summary of the symposium. Alcohol 34, 3-8.
34. Rajendran, R., Rajeesh, M.P., Shaikh, S., Shanthi, Pillai M.R., 2006. Expression of matrix metalloproteinases (MMP-1, MMP-2 and MMP-9) and their inhibitors (TIMP-1 and TIMP-2) in oral submucous fibrosis. Indian J. Dent. Res. 17, 161-166.
35. Sato, R., Maesawa, C., Fujisawa, K., Wada, K., Oikawa, K., Takikawa, Y., Suzuki, K., Oikawa, H., Ishikawa, K., Masuda, T., 2004. Prevention of critical telomere shortening by oestradiol in human normal hepatic cultured cells and carbon tetrachloride induced rat liver fibrosis. Gut. 53, 1001-1009. (Pubitemid 38824160)
36. Shibata, N., Watanabe, T., Okitsu, T., Sakaguchi, M., Takesue, M., Kunieda, T., Omoto, K., Yamamoto, S., Tanaka, N., Kobayashi, N., 2003. Establishment of an immortalized human hepatic stellate cell line to develop antifibrotic therapies. Cell Transplant 12, 499-507. (Pubitemid 36993193)
37. Shinkawa, H., Takemura, S., Minamiyama, Y., Kodai, S., Tsukioka, T., Osada-Oka, M., Kubo, S., Okada, S., Suehiro, S., 2009. S-allylcysteine is effective as a chemopreventive agent against porcine serum-induced hepatic fibrosis in rats. Osaka City Med. J. 55, 61-69.
38. Sumioka, T., Ikeda, K., Okada, Y., Yamanaka, O., Kitano, A., Saika, S., 2008. Inhibitory effect of blocking TGF-beta/Smad signal on injury-induced fibrosis of corneal endothelium. Mol. Vis. 14, 2272-2281.
39. Tien, Y.C., Lin, J.Y., Lai, C.H., Kuo, C.H., Lin, W.Y., Tsai, C.H., Tsai, F.J., Cheng, Y.C., Peng, W. H., Huang, C.Y., 2010. Carthamus tinctorius L. prevents LPS-induced TNFalpha signaling activation and cell apoptosis through JNK1/2-NFkappaB pathway inhibition in H9c2 cardiomyoblast cells. J. Ethnopharmacol. 130, 505-513.
40. Ueberham, E., Löw, R., Ueberham, U., Schönig, K., Bujard, H., Gebhardt, R., 2003. Conditional tetracycline-regulated expression of TGF-beta1 in liver of transgenic mice leads to reversible intermediary fibrosis. Hepatology 37, 1067-1078. (Pubitemid 36538683)
41. Varela-Rey, M., Montiel-Duarte, C., Osés-Prieto, J.A., López-Zabalza, M.J., Jaffrèzou, J.P., Rojkind, M., Iraburu, M.J., 2002. p38 MAPK mediates the regulation of alpha1(I) procollagen mRNA levels by TNF-alpha and TGF-beta in a cell line of rat hepatic stellate cells(1). FEBS Lett. 528, 133-138.
42. Velasco, G., Pendás, A.M., Fueyo, A., Knäuper, V., Murphy, G., López-Otín, C., 1999. Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members. J. Biol. Chem. 274, 4570-4576.
43. Walsh, K.M., Timms, P., Campbell, S., MacSween, R.N., Morris, A.J., 1999. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig. Dis. Sci. 44, 624-630.
44. Wei, X., Liu, H., Sun, X., Fu, F., Zhang, X., Wang, J., An, J., Ding, H., 2005. Hydroxysafflor yellow A protects rat brains against ischemia-reperfusion injury by antioxidant action. Neurosci. Lett. 386, 58-62.
45. Yamaguchi, M., Tsurusaki, Y., Misawa, H., Inagaki, S., Ma, Z.J., Takahashi, H., 2002. Potential role of regucalcin as a specific biochemical marker of chronic liver injury with carbon tetrachloride administration in rats. Mol. Cell Biochem. 241, 61-67.
46. Yang, C., Zeisberg, M., Mosterman, B., Sudhakar, A., Yerramalla, U., Holthaus, K., Xu, L., Eng, F., Afdhal, N., Kalluri, R., 2003. Liver fibrosis: insights intomigration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology 124, 147-159. (Pubitemid 36055348)